Cyano temozolomide API routed into hard gelatin capsule manufacture is charged as an assay-corrected unit dose, not as a fixed fraction of an excipient master blend. The dry blending sequence is selected because the tetrazine ring undergoes hydrolysis when exposed to aqueous media under neutral-to-alkaline conditions; therefore, tartaric acid is included in the formulation to maintain an acidic microenvironment around the drug particle. Release testing for the finished capsules is governed by 21 CFR 211.165 and 21 CFR 211.166, with content uniformity assessed according to USP <905> and dissolution assessed according to USP <711>. Degradation product control follows ICH Q3B(R2), and elemental impurities are evaluated through an ICH Q3D(R2) risk assessment. The oral capsule product must also meet the cleaning validation and contamination control requirements of 21 CFR 211.67 and 21 CFR 211.160 because the active substance is cytotoxic and requires dedicated or verified cleaned process contact surfaces.

The formulation addition ratio is expressed as label claim per filled capsule: 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, and 250 mg cyano temozolomide per unit, with potency-adjusted input set at 100.0% of label claim. Because low-dose and high-dose strengths require different excipient mass to maintain flow and weight sorting, the API-to-fill-weight percentage is not constant across the product range. Published reference labeling lists lactose anhydrous, colloidal silicon dioxide, sodium starch glycolate, tartaric acid, and stearic acid as inactive constituents; the sodium starch glycolate acts as a disintegrant, while the acidifier maintains a low-pH environment that stabilizes the active substance during storage and rapid disintegration in the gastric compartment.

Manufacture begins with pre-drying of excipients when ambient relative humidity exceeds 60%, followed by screening of the API and excipients through a 0.5 mm or equivalent mesh to remove agglomerates. The powders are blended in a low-shear tumbling blender until the blend uniformity acceptance criterion is met, then transferred to an automatic capsule filling machine equipped with weight sorting checkweighers and metal detection. In-process controls under 21 CFR 211.110 include fill weight, disintegration time, and moisture content; capsule shells are hard gelatin, and the finished units are packaged in high-density polyethylene bottles with desiccant canisters because moisture ingress can accelerate hydrolytic degradation.

The terminal product types are immediate-release hard gelatin capsules for oral administration, intended for once-daily dosing in approved oncology protocols. The capsule route covers the full adult dose range from low-dose adjuvant schedules to high-dose maintenance cycles. Batch release is not complete until the certificate of analysis demonstrates conformance to the approved specification for assay, related substances, water content, content uniformity, dissolution, and microbial limits.

What Changes When Cyano Temozolomide Is Lyophilized for Intravenous Administration?

Upon transfer from oral solid dosage handling to a sterile injectable line, cyano temozolomide is dissolved in Water for Injection rather than blended, and the process objective shifts from powder homogeneity to aseptic integrity and cake structure retention. The lyophilized formulation is selected because the drug substance undergoes hydrolytic degradation in aqueous solution, and a long-term ready-to-use liquid presentation would require pH conditions that are not compatible with intravenous infusion. Terminal sterilisation by moist heat is generally unsuitable for a thermally labile cytotoxic agent, so the manufacturing sequence relies on sterilising-grade filtration followed by aseptic filling and freeze-drying.

The injectable product is released under 21 CFR 211.113 and 21 CFR 211.84, with sterility tested to USP <71>, bacterial endotoxins to USP <85>, particulate matter to USP <788>, and visible particulates to USP <790>. Cleanroom classification for aseptic filling follows ISO 14644-1:2015 for ISO Class 5 critical zones with supporting ISO Class 7 environments. Reference lyophilized product labeling specifies 100 mg cyano temozolomide per single-dose vial, with 600 mg mannitol as bulking agent and 20 mg polysorbate 80 as wetting agent. The resulting API-to-bulking-agent ratio is 1:6, and the API-to-wetting-agent ratio is 5:1; these ratios are fixed by the approved registration file and are not interchangeable with capsule excipient ratios.

Manufacture starts with dissolution of the API in Water for Injection containing hydrochloric acid or another approved acidifying agent to maintain an acidic environment, followed by pH adjustment to the target range before sterile filtration through a 0.22 µm sterilising-grade membrane. The filtered solution is filled into Type I glass vials, partially stoppered, and loaded onto lyophilizer shelves. The freeze-drying cycle uses controlled shelf temperature and vacuum to remove water while maintaining cake structure and preventing meltback; the condenser temperature is maintained below the freezing point of the formulation. After drying, the vials are stoppered under vacuum or nitrogen, sealed with aluminum flip-off caps, and visually inspected. The lyophilized cake is reconstituted with 41 mL of Sterile Water for Injection to yield a nominal concentration of 2.5 mg/mL before dilution in 0.9% sodium chloride injection for intravenous infusion over 90 minutes. The terminal product type is a sterile lyophilized powder for intravenous infusion, presented as a single-dose vial that must be protected from light and used within the in-use stability period stated in the labeling.

When Film-Coated Tablets Replace Capsules in Regulatory-Approved Markets

In film-coated tablet manufacture, the hydrolytic sensitivity of cyano temozolomide is addressed by controlling the aqueous input of any wet granulation step and by selecting an acidified binder solution when wet granulation cannot be avoided. The compression process introduces additional constraints because over-lubrication delays dissolution, while insufficient compression produces friable cores that cannot withstand aqueous film coating. Tablet hardness, disintegration time, and moisture content are therefore monitored as in-process controls under 21 CFR 211.110, and finished tablets are tested against USP <701> for disintegration, USP <905> for uniformity of dosage units, USP <711> for dissolution, and USP <621> for assay and related substances. Impurity thresholds follow ICH Q3B(R2), and elemental impurity risk assessment follows ICH Q3D(R2).

Published tablet-specific master formulas are limited; the addition ratio must therefore be derived from development data rather than from a compendial default. As an arithmetic illustration, a 100 mg cyano temozolomide tablet core at a target mass of 400 mg places the API at 25% w/w, while a 250 mg dose in a 600 mg core places the API at 41.7% w/w. These values are not regulatory limits; they are used to frame the operating space for flow, compressibility, and content uniformity. Typical direct-compression excipients include microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, and tartaric acid or citric acid as acidic microenvironment stabilizers. The final coated tablet must maintain the same release profile constraints as the reference capsule unless an in vivo bioequivalence study supports a different dissolution specification.

Where the powder blend displays segregation potential or inadequate flow, roller compaction is preferred over aqueous wet granulation. The roller compaction step controls ribbon density by adjusting roll pressure and gap, and the granules are milled through a screen selected to provide a controlled particle size distribution that improves die fill. Final lubrication is performed in a low-shear blender after granulation, and compression is performed on a rotary tablet press with pre-compression and main compression stations. Aqueous film coating is applied only after core moisture and hardness limits are met; pan speed, spray rate, and inlet air temperature are selected to prevent core temperature from rising to a level that accelerates chemical degradation. The terminal product type is an immediate-release film-coated tablet for oral administration in strengths that may include 20 mg, 100 mg, and 250 mg in markets where such tablet presentations are authorized.

Because high-dose oral solid dosage products frequently require an intermediate with controlled bulk density and flow, cyano temozolomide is converted into granules before capsule filling or tablet compression when direct compaction cannot meet content uniformity and dissolution requirements. The granulation route is constrained by the need to avoid prolonged exposure of the drug to warm aqueous media; therefore, granulation fluid pH and drying endpoint are treated as critical process parameters. In-process verification under 21 CFR 211.110 includes granule moisture by loss-on-drying, sieve analysis, blend uniformity, and compatibility with the final dosage form. Finished product specifications for disintegration, dissolution, and content uniformity remain aligned with USP <701>, USP <711>, and USP <905>, while degradation products are quantified by USP <621> and reported against ICH Q3B(R2) thresholds.

The API-to-granulation feed ratio for high-dose development typically occupies a range of 20% w/w to 40% w/w, although this range is not a compendial requirement and is adjusted according to the bulk density, particle size distribution, and flow properties of the specific API lot. Low-dose strengths require different ratios to maintain uniformity without producing excessive granule mass. Representative granulation excipients include lactose monohydrate or dibasic calcium phosphate as filler, croscarmellose sodium as disintegrant, povidone as binder, and tartaric acid as acidifier; the binder is dissolved in a small volume of acidified aqueous vehicle to limit the contact time between the drug and water.

High-shear granulation is performed with a defined impeller tip speed and wet massing time, followed by wet sieving and fluid-bed drying at a product temperature that avoids hydrothermal decomposition. The dried granules are milled through a conical mill with a screen size selected to maintain target granule size distribution and to avoid overmilling, which would create fines that segregate during final blending. Magnesium stearate is added as a lubricant at a level established by compaction simulation and dissolution testing, because excessive lubrication can delay release and create content uniformity problems. The terminal product types obtained from this intermediate are capsules or tablets produced from the same granule matrix, with each batch reconciled against the master formula and released only after final product testing meets the approved specification.

For the 5 mg capsule strength, content uniformity rather than bulk flow is the dominant formulation constraint, and particle size control of cyano temozolomide becomes a critical upstream processing step. The API is processed through an air-jet mill or pin mill to reduce the particle size distribution and increase the number of active particles per unit dose, thereby reducing the risk of segregation in the blend. Release testing remains governed by USP <905> for content uniformity and USP <711> for dissolution, while particle size distribution is controlled as a raw material attribute under 21 CFR 211.84. Degradation products are controlled according to ICH Q3B(R2), and the micronization step must be validated to demonstrate that the short thermal and shear exposure does not generate new impurities or alter the crystalline form.

The addition ratio for low-dose encapsulation is defined by the dose per capsule rather than by a high API percentage; the 5 mg API is distributed into a larger excipient mass, and the API-to-fill-weight ratio may be below 5% w/w depending on the final fill weight selected for the capsule size. Because published fill-weight data for this specific configuration are limited, formulation work must establish the exact excipient masses through blend uniformity studies and process capability studies on the selected encapsulation machine. Geometric dilution and stepwise mixing are used to ensure distribution, and the final blend is sampled at multiple time points to verify that the relative standard deviation of assay values meets the acceptance criterion for content uniformity.

The terminal product types are immediate-release hard gelatin capsules in the 5 mg strength, used for low-dose oncology schedules and body-surface-area-adjusted regimens where such use is authorized. The manufacturing line is designed to contain cytotoxic dust, with split-valve transfer, double-bag charging, and air handling that maintains negative pressure relative to adjacent corridors. Cleaning validation follows 21 CFR 211.67, and analytical verification uses swab and rinse samples with calculated acceptable carryover limits. The final product is packaged with moisture protection and released against the full approved specification for assay, related substances, water content, content uniformity, and dissolution.